-
Concentra Biosciences Targets China-Based Biotech LianBio in Unsolicited Takeover Bid
•
LianBio (OTCMKTS: LIANY), a China-based biotech firm, has become the target of an unsolicited takeover bid by Concentra Biosciences LLC, a company controlled by private equity fund Tang Capital Partners LP. The cash offer is set at USD 4.30 per share for 100% of LianBio’s equity, a significant premium that…
-
FDA Investigates Safety of China-Made Plastic Syringes Due to Quality Concerns
•
The US Food and Drug Administration (FDA) has issued a warning that it is investigating the safety of plastic syringes manufactured in China, which are used for injecting or withdrawing fluids from patients. The notice is a broad warning about potential leaks, breakages, and other issues with all China-made syringes,…
-
China’s State Council Unveils Comprehensive Plan to Boost Beijing’s Healthcare Sector
•
The State Council has unveiled a comprehensive “Work Plan” aimed at enhancing Beijing’s service industry capabilities, with a particular focus on healthcare and medical services. Titled “Work Plan Supporting the Construction of Comprehensive Demonstration Zones to Deepen National Service Industry Openness in Beijing,” the document outlines several key proposals that…
-
Bayer Partners with CrossBay Medical to Enhance Hormonal IUS Delivery System
•
Germany’s Bayer (ETR: BAYN) has announced a strategic partnership with women’s health innovator CrossBay Medical to develop a user-friendly inserter designed for the delivery of Bayer’s hormonal intrauterine systems (IUSs) via the cervix. This collaboration seeks to enhance CrossBay’s CrossGlide inserter, transforming it into a single-handed device aimed at minimizing…
-
Johnson & Johnson Acquires Laminar for $400 Million to Enhance Heart Rhythm Solutions
•
Johnson & Johnson (J&J; NYSE: JNJ) has finalized the acquisition of medical device manufacturer Laminar for $400 million, along with potential milestone payments, integrating the company into its MedTech subsidiary, specifically within Biosense Webster, a division focused on heart rhythm disorders. Laminar’s innovative technology employs rotational motion to eliminate the…
-
MSD to Migrate IT Systems to AWS, Aiming for Faster Drug Discovery and Clinical Trials
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced plans to transition a significant portion of its IT infrastructure to Amazon Web Services (AWS), a move aimed at enhancing efficiency in drug discovery and clinical trial development. This multiyear initiative, revealed by parent company Amazon (NASDAQ: AMZN) this week, will…
-
Akeso’s AK111 Achieves Key Efficacy Milestones in Phase III Trial for Plaque Psoriasis
•
Akeso Biopharma (HKG: 9926), based in China, has announced that its pivotal Phase III clinical trial for the interleukin (IL)-17A monoclonal antibody (mAb) AK111 in moderate to severe plaque psoriasis has successfully met all primary efficacy endpoints, including PASI100 and sPGA0/1. This randomized, double-blind, placebo-controlled, multi-center study was designed to…
